China's New Mental Health Initiative Targets Youth and Innovation

China's National Health Commission plans to address gaps in mental health services from 2025-2027, focusing on youth. Eli Lilly joins a lawsuit over compounded drugs, and Neumora shares plummet after a depression drug trial failure.

China's National Health Commission announced efforts to improve mental health services from 2025 to 2027. With rising mental health issues, particularly among youth, the plan includes a hotline and regional centers.

Eli Lilly seeks to join a lawsuit against the FDA and compounding pharmacies. This involves the FDA's ruling that Lilly's weight-loss and diabetes drugs are no longer scarce, challenging cheaper versions sales.

Neumora Therapeutics' shares fell over 80% after a depression drug trial failed. The drug, navacaprant, did not reduce key symptoms in major depressive disorder patients during a pivotal study.

(With inputs from agencies.)